Jonathan R. Dry

4.0k citations

34 papers · 1.4k · 1 hit paper · h-index 19

Impact in

Cancer Research top 5%
- Cancer Genomics and Diagnostics
Oncology top 5%
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers

Papers in

Molecular Biology 30
- Melanoma and MAPK Pathways 5
- CRISPR and Genetic Engineering 4
- DNA Repair Mechanisms 4
- Bioinformatics and Genomic Networks 4
Cancer Research 11
- Cancer Genomics and Diagnostics 11

Co-authors: Robert McEwen (5 shared papers)J. Carl Barrett (5 shared papers)Zhongwu Lai (5 shared papers)Brian Dougherty (4 shared papers)Miika Ahdesmäki (2 shared papers)Aleksandra Markovets (1 shared paper)Brad Chapman (1 shared paper)Oliver Hofmann (1 shared paper)
Journals: Clinical Cancer Research (3 papers)Cancer Research (3 papers)Nature Communications (3 papers)Oncotarget (3 papers)BMC Cancer (2 papers)
Partner nations: United States United Kingdom Singapore

In The Last Decade

Jonathan R. Dry

33 papers receiving 1.4k citations

Jonathan R. Dry's Hit Papers

align trajectories log scale

VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research 2016 · 497 citations

Peers

Countries citing papers authored by Jonathan R. Dry

Since Specialization

Citations

This map shows the geographic impact of Jonathan R. Dry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan R. Dry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan R. Dry more than expected).

Fields of papers citing papers by Jonathan R. Dry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan R. Dry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan R. Dry. The network helps show where Jonathan R. Dry may publish in the future.

Co-authors

The 25 scholars most cited alongside Jonathan R. Dry, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jonathan R. Dry Line = papers co-authored together Jonathan R. Dry links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 34 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research Nucleic Acids Research ·Zhongwu Lai, Aleksandra Markovets, Miika Ahdesmäki, Brad Chapman, Oliver Hofmann, Robert McEwen, Justin Johnson, Brian Dougherty, J. Carl Barrett, Jonathan R. Dry Hit paper breakdown →	2016	497
2	Amplification of the Driving Oncogene, KRAS or BRAF , Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells Science Signaling ·Annette S. Little, Kathryn Balmanno, Matthew J. Sale, Scott Newman, Jonathan R. Dry, Mark Hampson, Paul A. Edwards, Paul D. Smith, Simon J. Cook	2011	161
3	Defining actionable mutations for oncology therapeutic development Nature reviews. Cancer ·T. Hedley Carr, Robert McEwen, Brian Dougherty, Justin Johnson, Jonathan R. Dry, Zhongwu Lai, Zara Ghazoui, Naomi Laing, Darren Hodgson, Francisco Cruzalegui, Simon J. Hollingsworth, J. Carl Barrett	2016	77
4	Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response Clinical Cancer Research ·Ben Sidders, Pei Zhang, Kelly Goodwin, Greg O’Connor, Deanna L. Russell, Alexandra Borodovsky, Joshua Armenia, Robert McEwen, Bolan Linghu, Johanna C. Bendell, Todd M. Bauer, Manish R. Patel, Gerald S. Falchook, Melinda S. Merchant, Gayle P. Pouliot, J. Carl Barrett, Jonathan R. Dry, Rich Woessner, Kris F. Sachsenmeier	2020	68
5	Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors Nature Communications ·Matthew J. Sale, Emma Minihane, Noel R. Monks, Rebecca Gilley, Frances M. Richards, Kevin Schifferli, Courtney L. Andersen, Emma Jane Davies, Mario Aladren Vicente, Eiko Ozono, Aleksandra Markovets, Jonathan R. Dry, Lisa Drew, Vikki Flemington, Theresa A. Proia, Duncan I. Jodrell, Paul D. Smith, Simon J. Cook	2019	51
6	Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer Nature Communications ·Anna Gogleva, Dimitris Polychronopoulos, Matthias Pfeifer, Vladimir Poroshin, M. Ughetto, Matthew J. Martin, Hannah Thorpe, Aurélie Bornot, Paul D. Smith, Ben Sidders, Jonathan R. Dry, Miika Ahdesmäki, Ultan McDermott, Eliseo Papa, Krishna C. Bulusu	2022	48
7	Stratification and prediction of drug synergy based on target functional similarity npj Systems Biology and Applications ·Mi Yang, Patricia Jaaks, Jonathan R. Dry, Mathew J. Garnett, Michael P. Menden, Julio Sáez-Rodríguez	2020	41
8	MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance Nature Communications ·Matthew J. Sale, Kathryn Balmanno, Jayeta Saxena, Eiko Ozono, Katarzyna Wojdyła, Rebecca E. McIntyre, Rebecca Gilley, Anna Woroniuk, Karen Howarth, Gareth Hughes, Jonathan R. Dry, Mark J. Arends, Pilar Caro, David Oxley, Susan Ashton, David J. Adams, Julio Sáez-Rodríguez, Paul D. Smith, Simon J. Cook	2019	41
9	A Correction to the Research Article Titled: “Amplification of the Driving Oncogene, KRAS or BRAF , Underpins Acquired Resistance to MEK1/2 Inhibitors in Colorectal Cancer Cells” by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. Cook Science Signaling ·Annette S. Little, Kathryn Balmanno, Matthew J. Sale, Scott Newman, Jonathan R. Dry, Mark Hampson, Paul A. Edwards, Paul D. Smith, Simon J. Cook	2011	34
10	Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients Clinical Cancer Research ·Justin Guinney, Charles Ferté, Jonathan R. Dry, Robert McEwen, Gilles Manceau, KJ Kao, Kai‐Ming Chang, Claus Bendtsen, Kevin Hudson, Erich Huang, Brian Dougherty, Michel Ducreux, Jean‐Charles Soria, Stephen Friend, Jonathan M.J. Derry, Pierre Laurent‐Puig	2013	30
11	Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets BMC Cancer ·Zhongwu Lai, Matthew Brosnan, Ethan S. Sokol, Mingchao Xie, Jonathan R. Dry, Elizabeth A. Harrington, J. Carl Barrett, Darren Hodgson	2022	28
12	Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort BMC Cancer ·Benjamin D. Leibowitz, Bonnie V. Dougherty, Joshua S. K. Bell, Joshuah Kapilivsky, Jackson Michuda, Andrew J. Sedgewick, Wesley Munson, Tushar A. Chandra, Jonathan R. Dry, Nike Beaubier, Catherine Igartua, Timothy Taxter	2022	28
13	Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055 Biochemical Society Transactions ·Gayle Marshall, Zoë Howard, Jonathan R. Dry, Sarah E. Fenton, Dan Heathcote, Neil Gray, Heather Keen, Armelle Logié, Sarah V. Holt, Paul D. Smith, Sylvie M. Guichard	2011	28
14	Looking beyond the cancer cell for effective drug combinations Genome Medicine ·Jonathan R. Dry, Mi Yang, Julio Sáez-Rodríguez	2016	26
15	Cell-Specific Computational Modeling of the PIM Pathway in Acute Myeloid Leukemia Cancer Research ·Dana Silverbush, Shaun Grosskurth, Dennis Wang, Francoise Powell, Berthold Göttgens, Jonathan R. Dry, Jasmin Fisher	2016	25
16	DeePaN: deep patient graph convolutional network integrating clinico-genomic evidence to stratify lung cancers for immunotherapy npj Digital Medicine ·Chao Fang, Dong Xu, Jing Su, Jonathan R. Dry, Bolan Linghu	2021	25
17	Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumours Oncotarget ·Liliana Ordonez, Trevor Hay, Robert McEwen, Urszula M. Polanska, Adina Hughes, Oona Delpuech, Elaine Cadogan, Steve Powell, Jonathan R. Dry, Giusy Tornillo, Lucy Silcock, Elisabetta Leo, Mark J. O’Connor, Alan R. Clarke, Matthew J. Smalley	2019	25
18	RNA-Seq Differentiates Tumour and Host mRNA Expression Changes Induced by Treatment of Human Tumour Xenografts with the VEGFR Tyrosine Kinase Inhibitor Cediranib PLoS ONE ·James Bradford, Matthew R. Farren, Steve Powell, Sarah Runswick, Susie Weston, Helen Brown, Oona Delpuech, Mark Wappett, Neil R. Smith, T. Hedley Carr, Jonathan R. Dry, Neil Gibson, Simon T. Barry	2013	24
19	The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells npj Precision Oncology ·Steven W. Criscione, Matthew J. Martin, Derek B. Oien, Aparna Gorthi, Ricardo J. Miragaia, Jingwen Zhang, Huawei Chen, Daniel Karl, Kerrin Mendler, Aleksandra Markovets, Sladjana Gagrica, Oona Delpuech, Jonathan R. Dry, Michael Grondine, Maureen M. Hattersley, Jelena Urosevic, Nicolas Floc’h, Lisa Drew, Yi Yao, Paul D. Smith	2022	22
20	Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547 Molecular Cancer Therapeutics ·Oona Delpuech, Claire Rooney, Lorraine Mooney, Dawn Baker, Robert A. Shaw, Michael Dymond, Dennis Wang, Pei Zhang, Sarah Cross, Margaret H. Veldman-Jones, Joanne Wilson, Barry R. Davies, Jonathan R. Dry, Elaine Kilgour, Paul D. Smith	2016	18

About Jonathan R. Dry

Jonathan R. Dry is a scholar working on Molecular Biology, Cancer Research, Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine, having authored 34 papers that have together received 1.4k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (11 papers), Melanoma and MAPK Pathways (5 papers), Lung Cancer Treatments and Mutations (5 papers), Computational Drug Discovery Methods (4 papers), PARP inhibition in cancer therapy (4 papers), CRISPR and Genetic Engineering (4 papers), DNA Repair Mechanisms (4 papers) and Bioinformatics and Genomic Networks (4 papers). The work is most often cited by research in Cancer Research (473 citations), Oncology (474 citations), Pathology and Forensic Medicine (228 citations), Molecular Biology (818 citations) and Physiology (49 citations). Jonathan R. Dry has collaborated with scholars based in United States, United Kingdom and Singapore. Frequent co-authors include Robert McEwen, J. Carl Barrett, Zhongwu Lai, Brian Dougherty, Miika Ahdesmäki, Aleksandra Markovets, Brad Chapman, Oliver Hofmann, Paul D. Smith and Simon J. Cook. Their work appears in journals such as Clinical Cancer Research, Cancer Research, Nature Communications, Oncotarget and BMC Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Jonathan R. Dry

Impact in

Papers in i

In The Last Decade

Jonathan R. Dry

Jonathan R. Dry's Hit Papers

Peers

Countries citing papers authored by Jonathan R. Dry

Fields of papers citing papers by Jonathan R. Dry

All Works

About Jonathan R. Dry

Explore authors with similar magnitude of impact

Papers in